For decades, LDL cholesterol, often referred to as 'bad cholesterol,' has been the primary measure for assessing cardiovascular risk, guiding both clinical guidelines and widespread statin use.While lowering LDL has proven benefits in reducing heart attacks, strokes, and early death, it does not provide a complete picture of risk.

LDL cholesterol tests measure the amount of cholesterol within particles, but not the number of particles themselves, which is a key factor in plaque buildup and artery blockage.

Apolipoprotein B (apoB) represents the total number of cholesterol-carrying particles and has emerged as a more precise predictor of cardiovascular events.

Despite evidence supporting its accuracy and cost-effectiveness, apoB testing is not widely adopted due to decades of reliance on LDL cholesterol, simplicity of the test, and established treatment protocols.

Experts emphasize that apoB alone does not indicate the underlying causes of elevated risk, which could range from high LDL to obesity or genetic factors.

The shift toward more detailed lipid testing, including lipoprotein(a) and remnant cholesterol, reflects a growing recognition that cardiovascular risk is complex and multi-faceted.

Early and personalized testing could improve prevention strategies, moving away from a single-number approach toward comprehensive risk assessment that integrates genetic, metabolic, and particle-based measurements.